Investigating the effects of beetroot on lung function in COVID-19 survivors
Assessment of Ventilatory Efficacy in Patients With Fatigue Associated With SARS-CoV2 Infection After Ingestion of Beet Juice
NA · Hospital de Mataró · NCT06217211
This study is testing if taking beetroot can help improve lung function and energy levels in people who are feeling tired and short of breath after recovering from COVID-19.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Hospital de Mataró (other) |
| Locations | 1 site (Mataró, Barcelona) |
| Trial ID | NCT06217211 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the impact of beetroot supplementation on lung function and muscle efficiency in patients experiencing fatigue after recovering from SARS-CoV-2 infection. It focuses on individuals who exhibit persistent symptoms, particularly dyspnea and fatigue, which are not of pulmonary origin but significantly affect their daily functionality. The methodology includes assessing mechanical efficiency through incremental exercise tests and analyzing muscle biopsies to understand the underlying physiological changes. The goal is to determine if beetroot can improve ventilation and overall physical performance in these patients.
Who should consider this trial
Good fit: Ideal candidates are individuals who have experienced fatigue following a SARS-CoV-2 infection and are willing to provide informed consent.
Not a fit: Patients with pre-existing cardiovascular, oncological, or neuromuscular conditions, or those with significant alcoholism or severe malnutrition, may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could enhance lung function and reduce fatigue in COVID-19 survivors, improving their quality of life.
How similar studies have performed: While the approach of using beetroot for improving muscle efficiency is novel in the context of post-COVID fatigue, similar interventions have shown promise in other conditions related to muscle performance.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with fatigue after SARS CoV2 infection. * Written informed consent signed by the study candidates (see Addendum 1), after receiving complete information about the objectives, techniques and possible consequences of the study. Exclusion Criteria: * Previous cardiovascular, oncological, neuromuscular or metabolic pathologies that could interfere with the results. * Significant alcoholism (\>80 g/day) or severe malnutrition * Chronic treatment with drugs with potential effects on muscle structure and function * Patient treated with nitrates * Patients diagnosed prior to the infection with fibromyalgia or chronic fatigue. * Patient who has a contraindication to carrying out a stress test. * Patients allergic to beets
Where this trial is running
Mataró, Barcelona
- Eulogio Pleguezuelos — Mataró, Barcelona, Spain (RECRUITING)
Study contacts
- Study coordinator: Eulogio Pleguezuelos, MD PhD
- Email: epleguezuelos@csdm.cat
- Phone: 937417700
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: SARS CoV 2 Infection, Muscle Disorder, Fatigue